Get the Stockscreener App
33.53
3.44%
-1.195
After Hours:
33.51
-0.025
-0.07%
Viking Therapeutics Inc stock is traded at $33.53, with a volume of 4.04M.
It is down -3.44% in the last 24 hours and up +45.24% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$34.73
Open:
$32.9
24h Volume:
4.04M
Relative Volume:
0.64
Market Cap:
$3.77B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-36.06
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-0.07%
1M Performance:
+45.24%
6M Performance:
+40.08%
1Y Performance:
-48.10%
1-Day Range:
$32.76
$34.89
1-Week Range:
$32.21
$36.80
52-Week Range:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
33.53 | 3.91B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts - sharewise.com
Viking Therapeutics (VKTX) Receives a Buy from Oppenheimer - MSN
Can trapped investors hope for a rebound in Viking Therapeutics Inc.Bond Market & Smart Investment Allocation Insights - newser.com
How to integrate Viking Therapeutics Inc. into portfolio analysis toolsStop Loss & High Conviction Investment Ideas - newser.com
Live market analysis of Viking Therapeutics Inc.2025 Major Catalysts & Capital Protection Trading Alerts - newser.com
Is Viking Therapeutics Inc. stock oversold or undervaluedWeekly Risk Summary & Technical Analysis for Trade Confirmation - Trung tâm Dự báo KTTV quốc gia
Why Viking Therapeutics Inc. stock attracts high net worth investorsJuly 2025 Spike Watch & Long-Term Investment Growth Plans - newser.com
Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have? - Yahoo Finance
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics - sharewise.com
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street? - sharewise.com
Earnings Preview: VKTX to Report Financial Results Post-market on October 22 - 富途牛牛
What to expect from Viking Therapeutics Inc. in the next 30 days2025 Valuation Update & Precise Buy Zone Tips - newser.com
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip? - MSN
How hedge fund analytics apply to Viking Therapeutics Inc. stockPortfolio Update Report & Fast Momentum Stock Entry Tips - newser.com
Viking Therapeutics (VKTX): Assessing Valuation as VK2735 Advances Through Late-Stage Obesity Drug Trials - simplywall.st
Did Viking Therapeutics Just Say "Checkmate" to Eli Lilly? - sharewise.com
Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025 - The Malaysian Reserve
Q3 2025 Results on Oct. 22 — Viking Therapeutics to Host Conference Call and Webcast - Stock Titan
Sector ETF performance correlation with Viking Therapeutics Inc.2025 Price Momentum & Low Risk Entry Point Guides - newser.com
How to build a custom watchlist for Viking Therapeutics Inc.Oil Prices & Consistent Growth Equity Picks - newser.com
Is a relief rally coming for Viking Therapeutics Inc. holdersNew Guidance & AI Powered Market Trend Analysis - newser.com
Can Viking Therapeutics Inc. stock hit record highs againJuly 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - newser.com
Using data models to predict Viking Therapeutics Inc. stock movement2025 Trading Recap & Reliable Volume Spike Trade Alerts - newser.com
Visualizing Viking Therapeutics Inc. stock with heatmapsJuly 2025 Fed Impact & Verified Swing Trading Watchlist - newser.com
Will Progress in VK2735 Weight Loss Trials Change Viking Therapeutics' (VKTX) Narrative? - simplywall.st
Chart based exit strategy for Viking Therapeutics Inc.Portfolio Update Report & Weekly Setup with High ROI Potential - newser.com
Why Shares in Viking Therapeutics Surged This Week - MSN
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note - sharewise.com
Earnings call transcript: Viking Therapeutics Q2 2025 sees increased R&D expenses - Investing.com
What makes Viking Therapeutics Inc. stock attractive to growth fundsJuly 2025 News Drivers & Proven Capital Preservation Tips - newser.com
Down 44%, Should You Buy the Dip on Viking Therapeutics? - sharewise.com
Key metrics from Viking Therapeutics Inc.’s quarterly dataWeekly Gains Summary & Long-Term Capital Growth Ideas - newser.com
Viking Therapeutics Inc. stock volume spike explained2025 Market Sentiment & Community Driven Trade Alerts - newser.com
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):